Gene therapy for breast and ovarian cancer with BRCA1

Breast Disease

Volumn 10, Issue 1-2, 1998, Pages 89-98

  Tait, David L ^a   Jensen, Roy A ^a   Holt, Jeffrey T ^a,c   Johnson, David H ^a   Gralow, Julie ^b   King, Mary Claire ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; NUCLEASE;

ARTICLE; BREAST CANCER; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; OVARY CANCER; PERITONITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

EID: 0031944672     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1998-101-211     Document Type: Article

References (34)

1. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89:21-39.
2. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset breast cancer to chromosome 17q21. Science 1990; 250:1684-1689.
3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
4. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 Mutations in Primary Breast and Ovarian Carcinomas. Science 1994; 266:120-122.
5. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994; 8:399-404.
6. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9:444-450.
7. Hosking L, Trowsdale J, Nicolai H, et al. A somatic BRCA1 mutation in an ovarian tumor. Nat Genet 1995; 9:343-344.
8. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. Nat Genet 1995; 9:439-443.
9. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995; 55:2998-3002.
10. Gayther SA, Mazoyer S, Warren W, et al. Germline mutations of the BRCA1 gene in breast/ovarian cancer families: evidence for a genotype/phenotype correlation. Nat Genet 1995; 11:428-433.
11. Holt JT, Thompson ME, Szabo C, et al. Growth retardation and tumor inhibition by BRCA1. Nat Genet 1996; 12:298-302.
12. Rao VN, Shao N, Ahmad M, Reddy ES. Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene 1996; 12:523-528
13. Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 1996; 13:1-7.
14. Wilson CA, Payton MN, Pekar SK et al. BRCA1 protein products: antibody specificity. Nat Genet 1996; 13:264-265.
15. Wilson CA, Payton MN, Elliott GS, et al. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene 1997; 14:1-16.
16. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997; 386:761-763.
17. Marquis ST, Rajan JV, Wynshaw-Boris A, et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995; 11:17-26.
18. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev 1995; 9:2712-2722.
19. Hakem R, de la Pompa JL, Sirard C, et al. The tumor suppressor gene Brca1 is required for embryonic proliferation in the mouse. Cell 1996; 85:1009-1023.
20. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88:265-275.
21. Jensen RA, Thompson ME, Szabo C, et al. BRCA1 is secreted and exhibits properties of a granin. Nat Genet 1996; 12:303-308.
22. Chen Y, Chen CF, Riley DJ, et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995; 270:789-791.
23. Scully R, Ganesan S, Brown M, et al. Location of BRCA1 in human breast and ovarian cancer cells. Science 1996; 272:123-126.
24. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996; 382:678-679.
25. Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 1996; 93:13595-13599.
26. Arteaga CL, Holt JT. Tissue-targeted antisense anti-fos retroviral vector inhibits established breast cancer in nude mice xenografts. Cancer Res 1996; 56:1098-1103.
27. Tait DL, Obermiller PS, Redlin-Frazier S, et al. A Phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 1997; 3:1959-1968.
28. Ayesh SK, Azar Y, Barghouti II, Ruedi JM, Babior BM, Matzner Y. Purification and characterization of a C5a-inactivating enzyme from human peritoneal fluid. Blood 1995; 85:3503-3509.
29. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA. Human serum lysis RNA tumor viruses. Nature 1975; 257:612-614.
30. Pensiero MN, Wysocki CA, Nader K, Kikuchi GE. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 1996; 7:1095-1101.
31. Rother RP, Squinto SP, Mason JM, Rollins SA. Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther 1995; 6:429-435.
32. Rother RP, Fodor WL, Springhorn JP, et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J Exp Med 1995; 182:1345-1355.
33. Rollins SA, Birks CW, Setter E, Squinto SP, Rother RP. Retroviral vector producer cell killing in human serum by natural antibody and complement: strategies for evading the humoral immune response. Hum Gene Ther 1996; 7:619-626.
34. Roth JA, Nguyen D, Lawrence DD, et al. Retroviral mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2:985-991.